DermaXon targets the brain-skin connection to discover and develop novel therapeutic strategies to treat life-threatening diseases and disorders such as pain, pruritus and genetic disorders of skin keratinization. The company core technology is based on the design and development of small molecules modulating multiple targets or inhibiting the degradation of endogenous molecules exhibiting polypharmacology. This polypharmacological approaches aim to understand and optimize the unknown off-targets activities for existing small molecules such as cannabinoids or retinoic acid. DermaXon uses medicinal chemistry, molecular biology and RNA sequencing to characterize and identify synergies and overlaps between biological signaling pathways modulated by small molecules.
| Website | http://dermaxon.com |
| Revenue | $8 million |
| Employees | 3 (2 on RocketReach) |
| Founded | 2013 |
| Address | 6610 Justin Ct, Missoula, Montana 59803, US |
| Phone | +1 832-677-3756 |
| Technologies |
JavaScript
,
HTML
,
PHP
+13 more
(view full list)
|
| Industry | Biotechnology, Pharmaceuticals, Healthcare |
| Keywords | Dermatology Research, Novel Therapeutics, Skin Research, Pain Management, Therapeutic Strategies, Drug Discovery, Life Threatening Diseases, Biotechnology, Pharmaceutical Research, New Treatments, Medical Innovation, Clinical Trials, Health Technology |
| Competitors | Obagi, SkinCeuticals, Neutrogena, RéVive Skincare, Kiehl's USA, Cerave, La Roche-Posay Laboratoire Dermatologique, Cetaphil US, Aveeno, Eucerin +47 more (view full list) |
| SIC | SIC Code 873 Companies, SIC Code 87 Companies |
| NAICS | NAICS Code 54 Companies, NAICS Code 541 Companies, NAICS Code 5417 Companies, NAICS Code 54171 Companies, NAICS Code 541714 Companies |
Looking for a particular DermaXon employee's phone or email?
The DermaXon annual revenue was $8 million in 2026.
2 people are employed at DermaXon.
DermaXon is based in Missoula, Montana.
The NAICS codes for DermaXon are [54, 541, 5417, 54171, 541714].
The SIC codes for DermaXon are [873, 87].